Compare CLNN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLNN | BRNS |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | 76 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 55.9M |
| IPO Year | N/A | 2021 |
| Metric | CLNN | BRNS |
|---|---|---|
| Price | $5.29 | $0.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $32.67 | $4.00 |
| AVG Volume (30 Days) | ★ 67.3K | 39.0K |
| Earning Date | 03-12-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.20 | N/A |
| Revenue Next Year | $20,465.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.28 | $0.56 |
| 52 Week High | $13.50 | $2.91 |
| Indicator | CLNN | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 49.25 |
| Support Level | $3.54 | $0.56 |
| Resistance Level | $5.71 | $0.76 |
| Average True Range (ATR) | 0.55 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 23.71 | 58.33 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.